SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Office ...

PHILADELPHIA, Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024. Details on the poster presentations at SITC 2024 are below: Title: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepato ...

NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually. Presentation details are as follows: Title: Therapeutic potential of CAN-3 ...

Core Insights - Lyell Immunopharma, Inc. announced the acceptance of three abstracts for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from Nov. 6-10, 2024, in Houston, TX, focusing on its pipeline of cell therapies and anti-exhaustion technology [1][2][4] Group 1: Clinical Trials and Presentations - The first presentation will showcase translational data from the LYL797 Phase 1 clinical trial, highlighting solid tumor infiltration and cell killing by reprogrammed ROR1 CAR T cells [2] - The second presentation will discuss multiomic profiling of LYL119, a reprogrammed ROR1 CAR T product, which generates T cells with reduced exhaustion and enhanced memory characteristics [3] - The third presentation will focus on utilizing Stim-R™ Technology to reduce irradiated feeder cells in the tumor-infiltrating lymphocyte culture process [3] Group 2: Company Overview - Lyell is a clinical-stage T-cell reprogramming company with a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for solid tumors and hematologic malignancies [4] - The company employs novel anti-exhaustion technology to address barriers such as T-cell exhaustion and lack of durable stemness, aiming for improved clinical outcomes [4] - Lyell is based in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington [4]

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024) taking place taking place in Houston, Texas on November 8-10, 2024. The first abstract accepted for poster presentation contains updated and expanded ...

WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Details for the ...

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company's Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024). The conference will be held in H ...

SITE Centers Corp. (SITC) has announced the completion of Curbline Properties spinoff. Recently, the retail REIT also provided an update on its transaction activity. Following the spin-off, Curbline has become an independent, publicly traded company that is trading today on the NYSE under the ticker symbol "CURB." Curbline is funded with $800 million in cash at the time of the spin-off, alongside a $400 million undrawn, unsecured line of credit and a $100 million unsecured, delayed draw term loan while carr ...

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX. "We are thrilled to be invited to present our data at this prestigious conference," stated Mi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, Par Value $0.10 Per Share SITC New York Stock Exchange Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n ...